Advanced search    

Search: authors:"Jeroen P. P. van Vugt"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Involving Patients in Weighting Benefits and Harms of Treatment in Parkinson's Disease

Introduction Little is known about how patients weigh benefits and harms of available treatments for Parkinson’s Disease (oral medication, deep brain stimulation, infusion therapy). In this study we have (1) elicited patient preferences for benefits, side effects and process characteristics of treatments and (2) measured patients’ preferred and perceived involvement in decision...

Feasibility of external rhythmic cueing with the Google Glass for improving gait in people with Parkinson’s disease

New mobile technologies like smartglasses can deliver external cues that may improve gait in people with Parkinson’s disease in their natural environment. However, the potential of these devices must first be assessed in controlled experiments. Therefore, we evaluated rhythmic visual and auditory cueing in a laboratory setting with a custom-made application for the Google Glass...

Balance Asymmetry in Parkinson’s Disease and Its Contribution to Freezing of Gait

and Its Contribution to Freezing of Gait Tjitske A. Boonstra 0 Jeroen P. P. van Vugt 0 Herman van der Kooij 0 Bastiaan R. Bloem 0 Natasha M. Maurits, University Medical Center Groningen UMCG

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease

To the editor:Keränen and colleagues have investigated the retention rate on pramipexole (PRX) among patients diagnosed with idiopathic Parkinson’s disease (PD) in a University Hospital in Finland. Moreover, they investigated reasons for PRX discontinuation, and they tried to identify determinants for PRX discontinuation. We welcome their study as a first initiative to identify...

Discontinuation of ropinirole and pramipexole in patients with Parkinson’s disease: clinical practice versus clinical trials

Objective To compare characteristics and incidence of discontinuation of Parkinson’s disease (PD) patients starting ropinirole or pramipexole in clinical practice with data from randomised controlled clinical trials (RCTs). Methods Included in the retrospective clinical-practice cohort were first-time users of ropinirole or pramipexole diagnosed with PD before 2005. Baseline...

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease

Objective To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson’s disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2 and DRD3 in a exploratory analysis. Methods Patients included were first-time users of the non-ergoline DA ropinirole or pramipexole who had been...